Font size
- 1 2 3 + Font size

click to adjust

Page tools
. Advanced search

A Targeted Approach to HealthCare

Bayer HealthCare Pharmaceuticals' goal is to discover products that will improve human health worldwide by diagnosing, preventing and treating diseases. As a specialty pharmaceutical company, we focus our efforts where we can have the most impact.

For more than 100 years, Bayer has been dedicated to developing, manufacturing and marketing pharmaceuticals. Built on the company's long history of providing medicines that healthcare providers and patients can trust, Bayer is one of the most recognized brands in health care.

Bayer News Releases

22 April 2014
FDA Grants Orphan Drug Designation for Bayer's Investigational Ciprofloxacin DPI (Dry Powder for Inhalation) for Treatment of Non-Cystic Fibrosis Bronchiectasis

11 April 2014
Bayer Launches New Educational Online Resource for Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

2 April 2014
Bayer Initiates Phase 3 Trial of Xofigo® (radium Ra 223 dichloride) Injection in Combination with Abiraterone Acetate for Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with Bone Predominant Metastatic Castration-Resistant Prostate Cancer

11 March 2014
Bayer to invest more than 500 million Euros for the manufacturing of hemophilia A products currently in development

11 March 2014
Bayer and Onyx Report Phase 3 Study Results of NEXAVAR® (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation

3 March 2014
Advocacy Organization Fight Colorectal Cancer and Bayer Kick-Start Colorectal Cancer Awareness Month at National Historic Landmark


Press Release Archive


Further Information

Clinical Trials

Information about clinical studies is available in the Bayer HealthCare database  as well as at

Copyright © Bayer Healthcare Pharmaceuticals